autoimmune diseases market in the us 2015-2019

10
Autoimmune Diseases Market in the US 2015- 2019 www.technavio.co m enquiry@technavi o.com

Upload: technavio

Post on 17-Aug-2015

34 views

Category:

Healthcare


1 download

TRANSCRIPT

Autoimmune Diseases Market in the US 2015-2019

[email protected]

USA – CANADA – UK – CHINA – INDIA

Autoimmune Diseases Market in the US 2015-2019

The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on theAutoimmune Diseases

Market in the US 2015-2019,please mail us at

[email protected]

USA – CANADA – UK – CHINA – INDIA

Key Trends

Technavio’s Senior Analyst says, “The high prevalence of autoimmune diseases is one of the major drivers in the market. An increasing number of people are being diagnosed with diseases such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. With the rise in the prevalence of autoimmune diseases, the demand for drugs is also increasing.”

• Autoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system produces autoantibodies that attack and destroy healthy tissues in the body rather than infectious agents.

• Technavio's analysts forecast the autoimmune diseases market in the US to grow at a CAGR of 6.17% over the period 2014-2019.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:

Autoimmune Diseases Market in the US 2015-2019

USA – CANADA – UK – CHINA – INDIA

USA – CANADA – UK – CHINA – INDIA

Vendors

To understand the vendor landscape and

for a full list of vendors view our

report:

Autoimmune Diseases Market in the US 2015-2019

AbbVie

Amgen

Biogen

AbbVie is a research-based pharmaceuticals company that discovers, develops, and commercializes advanced therapies for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis, low testosterone, and thyroid disease.

Amgen was incorporated in 1980 and is headquartered in Thousand Oaks, California, US. It is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

Biogen is a global biotechnology company engaged in the developing, manufacturing, and marketing of therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders. The company's principal products are Avonex, Tysabri, Rituxan, Fumaderm, Fampyra, and Tecfidera.

USA – CANADA – UK – CHINA – INDIA

Market Landscape

• The autoimmune diseases drugs market in the US is expected to grow at a moderate pace during the forecast period owing to the increased prevalence of autoimmune diseases.

• The expected launch of new drugs for the treatment of autoimmune diseases and government initiatives to improve people's access to drugs will also drive market growth.

• However, the high cost of therapy, complex nature of the disease, and shortage of accurate diagnostics will hamper market growth.

• The increase in R&D for developing novel therapies, in public awareness, and in strategic alliances among vendors will, however, propel the market.

• AbbVie, Amgen, Biogen, F. Hoffmann-La Roche, and Janssen Pharmaceuticals are the major vendors in the market. Humira, Enbrel, Rituxan, and Remicade are the top-selling drugs in the market.

USA – CANADA – UK – CHINA – INDIA

Key Buying Criteria • Vendors are increasingly entering into alliances with universities, research institutes, and

pharmaceutical companies for new drug development and to increase their market share.

• For instance, in 2015, Janssen-Cilag, a subsidiary of Janssen Pharmaceuticals, entered into an agreement with Monash University for the development of new medicines to treat rheumatoid arthritis and psoriasis.

• In 2014, MacroGenics and Takeda entered into an agreement for the development MGD010 for the treatment of systemic lupus erythematosus.

• In 2014, Kineta and Seattle Children's Research Institute announced the formation of an Alliance for Children's Therapeutics, a research collaboration for the development of new medicines in the treatment of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis.

• Similarly, in 2013, Daiichi Sankyo and Amplimmune formed an alliance for the development of AMP-110, a biologic meant for the treatment of rheumatoid arthritis.

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From Technavio?

Autoimmune Diseases Market in the US 2015-2019

Let us identify your needs.We would love to hear more!

USA – CANADA – UK – CHINA – INDIA

Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

[email protected]

We’ll include an hour with our analysts to discuss the report findings.

For free.

USA – CANADA – UK – CHINA – INDIA

Access the Report

USA – CANADA – UK – CHINA – INDIA

India: An Overview

USA – CANADA – UK – CHINA – INDIA

About Us

USA – CANADA – UK – CHINA – INDIA

Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501  

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION